Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693531 · ClinicalTrials.gov registry record
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
A clinical trial of Eosinophilic Esophagitis (EoE), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- 350
- Enrollment target
- 20
- Study locations
NCT06693531: Recruiting study of Eosinophilic Esophagitis (EoE), sponsored by Regeneron Pharmaceuticals.
NCT06693531 is a study of Eosinophilic Esophagitis (EoE) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 350 participants, above the 91-participant average among 10 other Eosinophilic Esophagitis (EoE) trials with a reported enrollment target (285% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06693531, a study of Eosinophilic Esophagitis (EoE), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure the following: * How EoE makes one feel * EoE signs and/or symptoms, eg, how difficult it is to swallow * How EoE affects quality-of-life * How EoE impacts aspects of daily life * How EoE symptoms have changed throughout the study
Conditions Studied
Interventions
- DRUG dupilumab
Study Locations (20)
California
- Scripps Clinic - La Jolla
- University of California Los Angeles (UCLA) - Los Angeles
- University of Southern California Keck School of Medicine - Los Angeles
- University of California, San Francisco - Oakland
- University of California San Francisco (UCSF) - San Francisco
Colorado
- Childrens Hospital Colorado - Aurora
- University of Colorado Anschutz Medical Campus - Aurora
- Rocky Mountain Gastroenterology - Littleton
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
- Northwestern University, Feinberg School of Medicine - Chicago
- Comprehensive Gastrointestinal Health, LLC - Libertyville
Arizona
- Phoenix Childrens Hospital - Phoenix
- Arizona Digestive Health/GI Alliance - Sun City
Connecticut
- UConn Health - The Carole and Ray Neag Comprehensive Cancer Center - Farmington
- Yale School of Medicine - New Haven
Florida
- Gastroenterology of Greater Orlando - Orange City
- Orlando Health - Orlando
Georgia
- Emory Healthcare, Emory Clinic - Atlanta
- GI Care for Kids LLC - Atlanta
Arkansas
- Arkansas Childrens Hospital - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-11-22 |
| Est. Completion | 2030-05-22 |
What NCT06693531 shows while recruiting
NCT06693531 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 91-participant average among 10 other Eosinophilic Esophagitis (EoE) trials with a reported enrollment target (285% higher).
The record links to 1 condition, with Eosinophilic Esophagitis (EoE) appearing as the primary indexed condition, and to 1 intervention - of which dupilumab is the first listed.
NCT06693531 names 20 study sites across 8 states, led by California, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT06693531 about?
NCT06693531 is a clinical study titled "A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care". This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others inc...
What is the current status of trial NCT06693531?
This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2024-11-22. Estimated completion is 2030-05-22.
What conditions does trial NCT06693531 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis (EoE).
What interventions are being tested in trial NCT06693531?
The interventions under investigation include: dupilumab (DRUG).
Who is sponsoring clinical trial NCT06693531?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693531 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis (EoE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06693531's enrollment target sits among peer trials
350 1st of 10 higher than 10 of 10 other Eosinophilic Esophagitis (EoE) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eosinophilic Esophagitis (EoE) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surface EMG Testing on Swallowing in EoE Patients
RECRUITING
-
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
RECRUITING · Phase 4
-
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
RECRUITING · Phase 3
-
Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy
RECRUITING
-
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI